These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33560612)

  • 21. Combination Therapies for Obesity.
    Camilleri M; Acosta A
    Metab Syndr Relat Disord; 2018 Oct; 16(8):390-394. PubMed ID: 29993319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
    Citrome L
    Int J Clin Pract; 2010 Oct; 64(11):1462-1465. PubMed ID: 20846190
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery.
    C Sudlow A; W le Roux C; J Pournaras D
    Obes Surg; 2019 Dec; 29(12):4095-4104. PubMed ID: 31650405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of obesity.
    Bray GA; Frühbeck G; Ryan DH; Wilding JP
    Lancet; 2016 May; 387(10031):1947-56. PubMed ID: 26868660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Makowski CT; Gwinn KM; Hurren KM
    Obes Facts; 2011; 4(6):489-94. PubMed ID: 22249001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of obesity in 2015.
    Shukla AP; Buniak WI; Aronne LJ
    J Cardiopulm Rehabil Prev; 2015; 35(2):81-92. PubMed ID: 25714749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
    Konstantinidou SK; Argyrakopoulou G; Simati S; Stefanakis K; Kokkinos A; Analitis A; Mantzoros CS
    Diabetes Obes Metab; 2024 Aug; 26(8):3147-3154. PubMed ID: 38757729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The limits and challenges of antiobesity pharmacotherapy.
    Gadde KM; Atkins KD
    Expert Opin Pharmacother; 2020 Aug; 21(11):1319-1328. PubMed ID: 32292094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
    Tronieri JS; Fabricatore AN; Wadden TA; Auerbach P; Endahl L; Sugimoto D; Rubino D
    Obes Facts; 2020; 13(6):572-583. PubMed ID: 33197917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
    Yanovski SZ; Yanovski JA
    JAMA; 2015 Mar 24-31; 313(12):1213-4. PubMed ID: 25803343
    [No Abstract]   [Full Text] [Related]  

  • 35. Approaches to obesity management.
    Sweeting AN; Caterson ID
    Intern Med J; 2017 Jul; 47(7):734-739. PubMed ID: 28677316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
    Billes SK; Sinnayah P; Cowley MA
    Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for Obesity.
    Saunders KH; Shukla AP; Igel LI; Kumar RB; Aronne LJ
    Endocrinol Metab Clin North Am; 2016 Sep; 45(3):521-38. PubMed ID: 27519128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of obesity: Available medications and drugs under investigation.
    Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
    Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of adjuvant weight loss medication after bariatric surgery.
    Nor Hanipah Z; Nasr EC; Bucak E; Schauer PR; Aminian A; Brethauer SA; Cetin D
    Surg Obes Relat Dis; 2018 Jan; 14(1):93-98. PubMed ID: 29287757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
    Halseth A; Shan K; Walsh B; Gilder K; Fujioka K
    Obesity (Silver Spring); 2017 Feb; 25(2):338-345. PubMed ID: 28026920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.